Invenra Highlights Exelixis' Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors

[
Invenra Highlights Exelixis' Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors
[og_img]
https://www.investing.com/news/press-releases/invenra-highlights-exelixis-initiation-of-phase-1-clinical-study-evaluating-xb628-a-firstinclass-bispecific-antibody-in-participants-with-recurrent-advanced-or-metastatic-solid-tumors-93CH-4043530


Investing.com